Hepatitis C Cure Effectiveness Assessment Test: Evaluating Sustained Virologic Response and Treatmen

The Hepatitis C Cure Effectiveness Assessment Test is a laboratory-based diagnostic evaluation used to confirm whether a patient has achieved a sustained virologic response (SVR) following antiviral therapy for hepatitis C virus (HCV) infection. By measuring HCV RNA levels in the blood at defined intervals after treatment completion, this test provides definitive evidence of viral eradication and guides long-term patient management. This article presents a comprehensive technical overview of the testing methodology, sample requirements, clinical applications, and interpretation standards used in modern HSV cure assessment.

Technical Overview

The Hepatitis C Cure Effectiveness Assessment Test is designed to verify viral eradication following completion of direct-acting antiviral (DAA) therapy or interferon-based regimens. The internationally accepted benchmark for cure is the sustained virologic response, defined as the absence of detectable HCV RNA in serum or plasma at a specified time point after the end of treatment. SVR12, measured at 12 weeks post-treatment, is the current clinical standard endorsed by major hepatology guidelines, while SVR24, measured at 24 weeks, is occasionally used in clinical trials and specific regulatory contexts.

Modern DAA regimens achieve SVR rates exceeding 95 percent across most genotypes, making accurate post-treatment verification essential for confirming cure, detecting rare relapse, and identifying reinfection in high-risk individuals. The assessment relies on highly sensitive molecular amplification techniques with a lower limit of quantification (LLOQ) of 15 IU/mL or below, ensuring that even very low-level residual viremia is reliably detected. Patients who achieve SVR experience normalization of liver enzymes, arrest of hepatic inflammation, and a substantial reduction in the risk of cirrhosis progression, hepatic decompensation, and hepatocellular carcinoma.

Testing Samples

Serum

Serum is the most widely accepted specimen type for HCV RNA quantification. Venous blood is collected in a plain tube or serum separator tube, allowed to clot at room temperature, and centrifuged to separate the serum fraction. The serum should be separated from the clot within two hours of collection to prevent degradation of viral RNA by nucleases present in whole blood.

Plasma

Plasma collected in EDTA anticoagulant tubes is equally suitable and is preferred in many molecular laboratories. Platelet-poor plasma is obtained by centrifugation, and the sample should be handled in a closed system to avoid contamination. Heparinized plasma is generally not recommended because heparin can inhibit polymerase chain reaction amplification.

Sample Storage and Transport

• Samples should be transported to the laboratory within 6 hours of collection when kept at 2 to 8 degrees Celsius.
• For delayed processing, serum or plasma can be stored at 2 to 8 degrees Celsius for up to 72 hours without significant RNA loss.
• For long-term storage prior to testing, aliquots should be frozen at minus 70 degrees Celsius or below to preserve nucleic acid integrity.
• Repeated freeze-thaw cycles must be avoided, as they degrade HCV RNA and may produce falsely low or negative results.

Sampling Time Points

• SVR12 assessment: blood drawn exactly 12 weeks after the final dose of antiviral therapy, the standard endpoint in clinical practice.
• SVR24 assessment: blood drawn 24 weeks after treatment completion, historically used to confirm durable response in clinical trials.
• Reinfection surveillance: periodic testing every 6 to 12 months for individuals with ongoing exposure risk, such as people who inject drugs.

Testing Items

The cure assessment panel comprises several complementary analytes that together provide a complete picture of treatment outcome and hepatic recovery:

• HCV RNA quantitative test (viral load): the core assay that measures the concentration of viral RNA in international units per milliliter, with results reported as quantified, detected below LLOQ, or target not detected.
• HCV RNA qualitative test: a presence-absence assay with analytical sensitivity comparable to quantitative platforms, used when confirmation of detection alone is sufficient.
• HCV core antigen test: an immunoassay-based marker of active viral replication that correlates closely with HCV RNA and offers a lower-cost alternative in resource-limited settings.
• Anti-HCV antibody test: retained for epidemiological context; it is important to note that antibodies persist for life after cure and cannot distinguish past resolved infection from active viremia.
• Liver function panel: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to document biochemical response and hepatic inflammation resolution.
• Hepatocellular carcinoma surveillance markers: alpha-fetoprotein (AFP) and imaging follow-up for patients with established cirrhosis, since HCC risk persists despite viral cure.

Testing Methods

Confirmation of cure is achieved through nucleic acid amplification testing (NAAT), which remains the reference methodology. Two principal platforms dominate clinical practice:

Real-Time Reverse Transcription Polymerase Chain Reaction

Automated real-time RT-PCR systems, such as the COBAS AmpliPrep/COBAS TaqMan and Abbott RealTime HCV assays, reverse-transcribe HCV RNA into complementary DNA and amplify target sequences with fluorescent probe detection. These platforms offer a linear quantification range typically spanning 15 to 100 million IU/mL, internal amplification controls to detect inhibition, and high analytical specificity across all known HCV genotypes.

Transcription-Mediated Amplification

TMA-based assays, such as the Hologic Aptima HCV Quant Dx, use isothermal RNA amplification with transcription of multiple RNA copies from a DNA intermediate. TMA demonstrates analytical sensitivity equivalent to RT-PCR, often reaching a detection threshold of approximately 10 to 15 IU/mL, and delivers rapid turnaround suitable for high-throughput laboratories.

HCV Core Antigen Immunoassay

Chemiluminescent microparticle immunoassays quantify the HCV core protein as a surrogate for viral replication. With a detection equivalence of roughly 3,000 IU/mL of HCV RNA, core antigen testing is less sensitive than molecular methods but provides a practical, cost-effective option for confirming cure in settings where molecular infrastructure is limited.

Result Interpretation

• Target not detected: no HCV RNA amplification, consistent with SVR when obtained at 12 or 24 weeks post-treatment.
• Detected below LLOQ: viral RNA present but not quantifiable; requires repeat testing after several weeks to rule out relapse versus a transient blip.
• Quantified result at or above LLOQ: indicates relapse, treatment failure, or reinfection, and warrants resistance-associated substitution testing and retreatment planning.
• Internal control failure: sample inhibition or inadequate specimen volume; the specimen must be recollected and retested.

Applications

• Post-treatment cure confirmation for patients completing DAA therapy, documenting SVR12 as the definitive clinical endpoint.
• Follow-up evaluation after interferon-based or sofosbuvir-containing regimens in regions with legacy treatment programs.
• Reinfection monitoring in people who inject drugs, HIV-HCV coinfected patients, and incarcerated populations with ongoing exposure risk.
• Primary endpoint measurement in clinical trials evaluating new antiviral combinations and treatment durations.
• Support for national and World Health Organization hepatitis C elimination initiatives, which require verified cure data for cascade-of-care reporting toward 2030 targets.
• Pre-transplant and post-transplant virological assessment to guide donor-recipient management and prophylactic strategies.
• Occupational and vertical exposure follow-up, confirming spontaneous clearance or treatment success after documented infection events.

FAQ

When should the cure assessment test be performed?

Testing should be performed 12 weeks after the final dose of antiviral medication. A target-not-detected result at this time point constitutes SVR12 and confirms cure. Some clinicians repeat testing at 24 weeks for additional confirmation, particularly in cirrhotic patients or clinical trial participants.

Does a negative HCV antibody test confirm cure?

No. Anti-HCV antibodies persist indefinitely in nearly all cured individuals and are markers of past exposure rather than active infection. Only a molecular HCV RNA test can confirm viral eradication.

Can hepatitis C return after achieving SVR?

True late relapse after SVR12 is extremely rare, occurring in less than 1 percent of cases. However, reinfection is possible following new exposure through high-risk behaviors, which is why periodic retesting is recommended for individuals with ongoing risk factors.

What does a result of detected below LLOQ mean?

This indicates that trace viral RNA was detected at a level beneath the assay quantification threshold. Guidelines recommend repeating the HCV RNA test within 3 to 6 months; persistence or an increase in viral load suggests relapse, whereas reversion to target not detected supports cure.

Do cured patients still require liver monitoring?

Yes. Patients with cirrhosis or significant fibrosis remain at elevated risk for hepatocellular carcinoma despite viral cure and should undergo surveillance with liver ultrasound and AFP every 6 months, as recommended by hepatology associations.

Is a single SVR12 test sufficient to declare cure?

In immunocompetent patients with standard-risk profiles, a single target-not-detected result at 12 weeks post-treatment is considered sufficient evidence of cure. Additional testing is reserved for immunocompromised patients, clinical trial protocols, or when clinical suspicion of relapse or reinfection arises.